Emblaveo will be available in the third quarter of 2025 to treat patients with intra-abdominal infections, a common cause of sepsis in the intensive care unit.

AbbVie receives US FDA approval for Emblaveo to treat adults with complicated intra-abdominal infections with limited or no treatment options: North Chicago, Illinois Monday, Febr ...

In REVISIT, study participants with cIAI (n=312) were randomly assigned 2:1 to receive aztreonam-avibactam + metronidazole or meropenem ± colistin for 5 to 14 days of therapy. The primary ...

Ten months after Pfizer scored approval in Europe for Emblaveo (aztreonam and avibactam) to treat complicated intra-abdominal infections (cIAIs), AbbVie has done the same in the U.S., winning an ...

This study reveals that SHANK3 deficiency in brain endothelial cells disrupts BBB function during the neonatal period through β-Catenin imbalance, leading to ASD-related neuronal and behavioral ...

Clinical trials conducted in patients with CAP treated on an outpatient basis provide relevant data for clinicians dealing with management of this common serious infection. A number of trials have ...

Abstract and Introduction Empirical Antimicrobial Therapy Against Gram-negative Pathogens Adverse Consequences Related to Combination Antimicrobial Use Conclusion References A recent retrospective ...